Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $32.72M rose 67.2% year over year, ahead of the +58.7% change in trailing-twelve-month research & development. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +118.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +67.2% holds above the trailing-twelve-month pace of +58.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 94.79M USD
- Year-over-year change
- +55.6%
- 3-year CAGR
- +118.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.79M | +55.6% |
| FY2024 | 2024-12-31 | 60.94M | +117.6% |
| FY2023 | 2023-12-31 | 28M | +207.2% |
| FY2022 | 2022-12-31 | 9.12M | — |
Research & Development vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 research & development of $107.93M is the 6th highest of the 10 companies compared; the peer median is $162.51M.
- Its year-over-year change of +58.7% is the 2nd highest of 9, against a peer median of +3.9%.
- Research & development amounts to 539.7% of revenue for RAPP, versus a peer median of 25.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $187.86M | -3.5% | +46.8% | 24.2% | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M | +11.3% | +45.0% | — |
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $162.51M | +3.9% | +24.4% | 25.4% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 112K | 839K | 1.02M |
| Gross Profit | (15K) | (112K) | (839K) | (1.02M) |
| Gross Margin | — | — | — | — |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| Depreciation & Amortization | 15K | 112K | 839K | 1.02M |
| EBITDA | (10.35M) | (34.66M) | (77.47M) | (124.08M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (10.37M) | (36.18M) | (83.06M) | (125.1M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income / Expenses | (285K) | 1.4M | 4.75M | 13.62M |
| Income Before Tax | (10.65M) | (34.78M) | (78.31M) | (111.48M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 10K | 0 | 0 |
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.29) | (0.95) | (3.78) | (2.86) |
| EPS (Diluted) | (0.29) | (0.95) | (3.78) | (2.86) |
| Weighted Avg Shares | 20.12M | 18.08M | 20.74M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.12M | 18.08M | 20.74M | 46.98M |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.